Abstract
Objective
To investigatethe sleep-wake cycle and theeffects of cabergoline monotherapyin a homogenous group of de novoParkinson’s Disease (PD) patientswithout confounding comorbidfactors.
Design and participants
Twelve de novo patients affected byidiopathic PD underwent twoambulatory polysomnographic (APSG)monitoring sessions. The firstwas performed at baseline, and thesecond recording one-month afterstable treatment with cabergolinemonotherapy. Subjective daytimesleepiness was evaluated by meansof the Epworth Sleepiness Scale.Data obtained in PD patients atbaseline were compared with thoseobtained in 12 age- and sexmatchedhealthy subjects.
Results
Diurnal sleep parameters did notshow significant differencesbetween controls and PD patientsat baseline. In PD patients, nosignificant changes in diurnal sleepwere observed between baselineand cabergoline treatment. Regardingnocturnal sleep, patients atbaseline showed a significantlylower sleep efficiency and a significantlyhigher Wakefulness AfterSleep Onset than controls. Withrespect to baseline, a significantincrease in REM latency and asignificant reduction in REM sleepwere observed during cabergolinetreatment.
Conclusions
In the earlystage of PD, the neurodegenerativeprocess does not seem to be directlyresponsible for daytimesomnolence, but it may be directlyinvolved in the alteration of nocturnalsleep. Cabergoline monotherapydoes not affect daytimesleep propensity and, despite clinicalimprovement, it may have negativeeffects on REM sleep.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Tandberg E, Larsen JP, Karlsen K(1998) A community-based study ofsleep disorders in patients with Parkinson’sdisease. Mov Disord 13(6):895–899
Ondo WG, Dat Vuong K, Khan H,Atassi F, Kwak C, Jankovic J (2001)Daytime sleepiness and other sleepdisorders in Parkinson’s disease. Neurology57(8):1392–1396
Tan EK, Lum Sy, Fook-Chong SM, TeohML, Yih Y, Tan L, Tan A, Wong MC(2002) Evaluation of somnolence inParkinson’s disease: comparison withage- and sex-matched controls. Neurology5(3):465–468
Frucht S, Rogers JD, Greene PE,Gordon MF, Fahn S (1999) Fallingasleep at the wheel: motor vehiclemishaps in person taking pramipexoleand ropirinole. Neurology 52(9):1908–1910
Ferreira JJ, Galitzky M, Montastruc JL,Rascol O (2000) Sleep attacks andParkinson’s disease treatment. Lancet355(9212):1333–1334
Ulivelli M, Rossi S, Lombardi C,Bartalini S, Rocchi R, Giannini F,Passero S, Battistini N, Lugaresi E(2002) Polysomnographic characterizationof pergolide-induced sleepattacks in idiopathic PD. Neurology58(3):462–465
Homann CN, Wenzel K, Suppan K,Ivanic G, Kriechbaum N, Crevenna R,Ott E (2002) Sleep attacks in patienttaking dopamine agonists: review.BMJ 324(7352):1483–1487
Garcia-Borreguero D, Schwarz C,Larrosa O, de la Llave Y, Garcia deYebenes J (2003) L-DOPA-inducedexcessive daytime somnolence in PD:a placebo-controlled case with MSLTassessment. Neurology 61(7):1008–1010
Poewe W, Hogl B (2000) Parkinson’sdisease and sleep. Curr Opin Neurol13(4):423–426
Rye DB, Jankovic J (2002) Emergingviews of dopamine in modulationsleep/wake state from unlike source:PD. Neurology 58(3):341–346
Arnulf I, Konofal E, Merino-Andreu M,Houeto JL, Mesnage V, Welter ML,Lacomblez L, Golmard JL, Derenne JP,Agid Y (2002) Parkinson’s disease andsleepiness: an integral part of PD.Neurology 58(7):1019–1024
Romigi A, Brusa L, Marciani MG,Pierantozzi M, Placidi F, Izzi F, Sperli F,Testa F, Stanzione P (2005) Sleepepisodes and daytime somnolence asresult of individual susceptibility todifferent dopaminergic drugs in a PDpatient: a polysomnographic study.J Neurol Sci 228(1):7–10
Garcia-Borreguero D, Lardosa O, BravoM (2003) Parkinson’s disease andsleep. Sleep Med Rev 7(2):115–129
Fariello RG (1998) Pharmacodynamicand pharmacokinetics features ofcabergoline. Rationale for use inParkinson’s disease. Drugs 55(Suppl1):10–16
Romigi A, Stanzione P, Marciani MG,Izzi F, Placidi F, Cervellino A, GiacominiP, Brusa L, Grossi K, PierantozziM (2006) Effect of cabergoline addedto levodopa treatment on sleep-wakecycle in idiopathic Parkison’s disease:an open label 24-hour polysomnographicstudy. J Neural Transm113(12):1909–1913
Hogl B, Rothdach A, Wetter TC, TrenkwalderC (2003) The effect of cabergolineon sleep, periodic leg movementsin sleep, and early morning motorfunction in patients with parkinson’sdisease. Neuropsychopharmacology28:1866–1870
Hoehn MH, Yahr MD (1967) Parkinsonism:onset, progression andmortality. Neurology 17:427–442
Fahn S, Elton RL, Members of theUPDRS development committeeUnified Parkinson’s disease ratingscale (1997) In: Fahn S, Marsden CD,Calne DB, Goldstein M (eds) Recentdevelopment in Parkinson’s disease,Vol. 2 MacMillan Healthcare Information:Florham Park, NJ, pp 153–163;293–304
Johns MW (1991) A new method formeasuring daytime sleepiness: theEpworth sleepiness scale. Sleep 14(6):540–545
Rechtshaffen A, Kales A (1968) A manualof standardized terminology,techniques and scoring system forsleep stages of human subjects. UCLABrain Information Service/BrainResearch Institute, Los Angeles
Lapierre O, Montplaisir J (1992) Polysomnographicfeatures of REM sleepbehavior disorder: development of ascoring method. Neurology 42(7):1371–1374
Olanow CW, Schapira AH, Roth T(2000) Waking up to sleep episodes inParkinson’s disease. Mov Disord15(2):212–215
Wetter TC, Collado-Seidel V, PollmacherT , Yassouridi SA, TrenkwalderC (2000) Sleep and periodic leg movementpattern in drug-free patient withParkinson’s disease and multiple systematrophy. Sleep 23(3):361–367
Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ (1990) Sleepdisorders and sleep effect in Parkinson’sdisease. Mov Disord 5(4):280–285
Hogl BE, Gomez-Averalo G, Garcia S,Scipioni O, Rubio M, Blanco M, GershanikOS (1998) A clinical, pharmacologic,and polysomnographic study ofsleep benefit in Parkinson’s disease.Neurology 50(5):1332–1339
Manni R, Terzaghi M, Sartori I, ManciniF, Pacchetti C (2004) Dopamineagonists and sleepiness in PD: reviewof the literature and personal findings.Sleep Medicine 5:189–193
Chaudhuri KR, Pal S, Brefel-CourbonC (2002) ‘Sleep attacks’ or ‘unintendedsleep episodes’ occur with dopamineagonists: is this a class effect? Drug Saf25(7):473–483
Carskadon MA, Dement WC (1992)Multiple sleep latency tests during theconstant routine. Sleep 15(5):396–399
Gigli GL, Placidi F, Diomedi M,Maschio M, Silvestri G, Scalise A,Marciani MG (1996) Sleep in healthyelderly subjects: a 24-hour polysomnographicstudy. Int J Neurosci 85(3–4):263–271
Del Dotto P, et al. (2003) Bedtime cabergolinein Parkinson’s disease patientswith excessive daytime somnolence inducedby dopamine agonists. NeurolSci 24(3):170–171
Rye DB, Johnston LH, Watts RL, BliwiseDL (1999) Juvenile Parkinson’s diseasewith REM sleep behavior disorders,sleepiness and daytime REM onset.Neurology 53(8):1868–1870
Arnulf I, Bonnet AM, Damier P, BejjaniBP, Seilhean D, Derenne JP, Agid Y(2000) Hallucinations, REM sleep andParkinson’s disease: a medical hypo thesis.Neurology 55(2):281–288
Gagnon JF, Bedard MA, Fantini ML,Petit D, Panisset M, Rompre S, CarrierJ, Montplaisir J (2002) REM sleepbehavior disorder and REM sleepwithout atonia in Parkinson’s disease.Neurology 59(4):585–589
Carrier J, Frenette S, Montplaisir J,Paquet GJ, Drapeau C, Morettini J(2005) Effects of Periodic Leg Movementsduring sleep in middle-agedsubjects without sleep complaints. MovDisord 20(9):1127–1132
Bergonzi P, Chiurulla C, Gambi D,Mennuni G, Pinto F (1975) L-dopa plusdopa-decarboxylase inhibitor. Sleeporganization in Parkinson’s syndromebefore and after treatment. Acta NeurolBelg 75(1):5–10
Brunner H, Wetter TC, Hogl B, YassouridisA, Trenkwalder C, Friess E (2002)Microstructure of the non-rapid eyemovement sleep electroencephalogramin patients with newly diagnosedParkinson’s disease: effects of dopaminergictreatment. Mov Disord 17(5):928–933
Cianchetti C, Masala C, Mangoni A,Gessa GL (1980) Suppression of REMand delta sleep by apomorphine inman: a dopamine mimetic effect.Psychopharmacology (Berl) 67(1):61–65
Askenasy JJ, Yahr MD (1984) Suppressionof REM rebound by Pergolide. JNeural Transm 59(2):151–159
Charles R (2002) Dopamine agonistsand sleep in Parkinson’s disease. Neurology58:71–78
Braak H, Ghebremedhin E, Rub U,Bratzke H, Del Tredici K (2004) Stagesin the development of Parkinson’sdisease-related pathology. Cell TissueRes 318(1):121–134
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was performed at the SleepDisorder Center of Tor Vergata Universityof Rome.
The authors have declared that no conflictof interest exists.
Rights and permissions
About this article
Cite this article
Placidi, F., Izzi, F., Romigi, A. et al. Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson’s disease patients. J Neurol 255, 1032–1037 (2008). https://doi.org/10.1007/s00415-008-0836-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-008-0836-4